GCG and type 2 diabetes mellitus: Long‐term efficacy and safety of pharmacotherapies to prevent T2D and CVD and reduce intermediate risk factors (dyslipidaemia, hypertension, prediabetes) in this population are not known and larger trials of incretin‐based and other therapies are needed to build the evidence base and support clinical guidance considering their young age and maternal and foetal outcomes of possible future pregnancies.